FDA Steps Up Alzheimer’s Initiatives, Plans October Stakeholders Meeting

Drug treatments and biomarker development for Alzheimer's disease are on the agenda of a meeting FDA expects to hold in October with neurology organizations, Janet Woodcock, the agency's chief medical officer, said during a July 25 audio conference sponsored by Avalere

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet